These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30643190)

  • 1. Mechanisms involved in the activation of C/EBPα by small activating RNA in hepatocellular carcinoma.
    Zhao X; Reebye V; Hitchen P; Fan J; Jiang H; Sætrom P; Rossi J; Habib NA; Huang KW
    Oncogene; 2019 May; 38(18):3446-3457. PubMed ID: 30643190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer.
    Voutila J; Reebye V; Roberts TC; Protopapa P; Andrikakou P; Blakey DC; Habib R; Huber H; Saetrom P; Rossi JJ; Habib NA
    Mol Ther; 2017 Dec; 25(12):2705-2714. PubMed ID: 28882451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma.
    Setten RL; Lightfoot HL; Habib NA; Rossi JJ
    Curr Pharm Biotechnol; 2018; 19(8):611-621. PubMed ID: 29886828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C/EBPalpha is up-regulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation.
    Lu GD; Leung CH; Yan B; Tan CM; Low SY; Aung MO; Salto-Tellez M; Lim SG; Hooi SC
    Gastroenterology; 2010 Aug; 139(2):632-43, 643.e1-4. PubMed ID: 20347819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo.
    Reebye V; Sætrom P; Mintz PJ; Huang KW; Swiderski P; Peng L; Liu C; Liu X; Lindkaer-Jensen S; Zacharoulis D; Kostomitsopoulos N; Kasahara N; Nicholls JP; Jiao LR; Pai M; Spalding DR; Mizandari M; Chikovani T; Emara MM; Haoudi A; Tomalia DA; Rossi JJ; Habib NA
    Hepatology; 2014 Jan; 59(1):216-27. PubMed ID: 23929703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Liver Cancer by C/EBPA saRNA.
    Zhao X; Voutila J; Ghobrial S; Habib NA; Reebye V
    Adv Exp Med Biol; 2017; 983():189-194. PubMed ID: 28639200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.
    Reebye V; Huang KW; Lin V; Jarvis S; Cutilas P; Dorman S; Ciriello S; Andrikakou P; Voutila J; Saetrom P; Mintz PJ; Reccia I; Rossi JJ; Huber H; Habib R; Kostomitsopoulos N; Blakey DC; Habib NA
    Oncogene; 2018 Jun; 37(24):3216-3228. PubMed ID: 29511346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted delivery of CEBPA-saRNA for the treatment of pancreatic ductal adenocarcinoma by transferrin receptor aptamer decorated tetrahedral framework nucleic acid.
    Wang L; Yao Q; Guo X; Wang B; Si J; Wang X; Jing S; Yan M; Shi Y; Song G; Shen X; Guan J; Zhao Y; Zhu C
    J Nanobiotechnology; 2024 Jul; 22(1):392. PubMed ID: 38965606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C/EBPα Short-Activating RNA Suppresses Metastasis of Hepatocellular Carcinoma through Inhibiting EGFR/β-Catenin Signaling Mediated EMT.
    Huan H; Wen X; Chen X; Wu L; Liu W; Habib NA; Bie P; Xia F
    PLoS One; 2016; 11(4):e0153117. PubMed ID: 27050434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCAAT-enhancer binding protein-α (C/EBPα) and hepatocyte nuclear factor 4α (HNF4α) regulate expression of the human fructose-1,6-bisphosphatase 1 (FBP1) gene in human hepatocellular carcinoma HepG2 cells.
    Wattanavanitchakorn S; Rojvirat P; Chavalit T; MacDonald MJ; Jitrapakdee S
    PLoS One; 2018; 13(3):e0194252. PubMed ID: 29566023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter-associated small double-stranded RNA interacts with heterogeneous nuclear ribonucleoprotein A2/B1 to induce transcriptional activation.
    Hu J; Chen Z; Xia D; Wu J; Xu H; Ye ZQ
    Biochem J; 2012 Nov; 447(3):407-16. PubMed ID: 23035981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
    Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
    Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small activating RNA upregulates NIS expression: promising potential for hepatocellular carcinoma endoradiotherapy.
    Xia W; Li D; Wang G; Ni J; Zhuang J; Ha M; Wang J; Ye Y
    Cancer Gene Ther; 2016 Oct; 23(10):333-340. PubMed ID: 27608773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma.
    Zeng C; Wang R; Li D; Lin XJ; Wei QK; Yuan Y; Wang Q; Chen W; Zhuang SM
    Hepatology; 2010 Nov; 52(5):1702-12. PubMed ID: 21038412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice.
    Zhou J; Li H; Xia X; Herrera A; Pollock N; Reebye V; Sodergren MH; Dorman S; Littman BH; Doogan D; Huang KW; Habib R; Blakey D; Habib NA; Rossi JJ
    Mol Ther; 2019 May; 27(5):999-1016. PubMed ID: 30852139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial.
    Sarker D; Plummer R; Meyer T; Sodergren MH; Basu B; Chee CE; Huang KW; Palmer DH; Ma YT; Evans TRJ; Spalding DRC; Pai M; Sharma R; Pinato DJ; Spicer J; Hunter S; Kwatra V; Nicholls JP; Collin D; Nutbrown R; Glenny H; Fairbairn S; Reebye V; Voutila J; Dorman S; Andrikakou P; Lloyd P; Felstead S; Vasara J; Habib R; Wood C; Saetrom P; Huber HE; Blakey DC; Rossi JJ; Habib N
    Clin Cancer Res; 2020 Aug; 26(15):3936-3946. PubMed ID: 32357963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yin Yang-1 suppresses differentiation of hepatocellular carcinoma cells through the downregulation of CCAAT/enhancer-binding protein alpha.
    Zhang S; Jiang T; Feng L; Sun J; Lu H; Wang Q; Pan M; Huang D; Wang X; Wang L; Jin H
    J Mol Med (Berl); 2012 Sep; 90(9):1069-77. PubMed ID: 22391813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer.
    Hashimoto A; Sarker D; Reebye V; Jarvis S; Sodergren MH; Kossenkov A; Sanseviero E; Raulf N; Vasara J; Andrikakou P; Meyer T; Huang KW; Plummer R; Chee CE; Spalding D; Pai M; Khan S; Pinato DJ; Sharma R; Basu B; Palmer D; Ma YT; Evans J; Habib R; Martirosyan A; Elasri N; Reynaud A; Rossi JJ; Cobbold M; Habib NA; Gabrilovich DI
    Clin Cancer Res; 2021 Nov; 27(21):5961-5978. PubMed ID: 34407972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Airway epithelial cell differentiation during lung organogenesis requires C/EBPα and C/EBPβ.
    Roos AB; Berg T; Barton JL; Didon L; Nord M
    Dev Dyn; 2012 May; 241(5):911-23. PubMed ID: 22411169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. shRNA-mediated silencing of the RFC3 gene suppresses hepatocellular carcinoma cell proliferation.
    Yao Z; Hu K; Huang H; Xu S; Wang Q; Zhang P; Yang P; Liu B
    Int J Mol Med; 2015 Nov; 36(5):1393-9. PubMed ID: 26397132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.